Pharvaris N.V.

Pharvaris N.V.

World Rank (Jan-05-2024)
7,301
Market Cap (Jan-05-2024)
1.326 Billion USD
World Rank (Jul-30-2023)
11,900
Market Cap (Jul-30-2023)
0.573 Billion USD
World Rank (Jan-07-2022)
11,928
Market Cap (Jan-07-2022)
0.639 Billion USD
World Rank (Jan-01-2021)
10,727
Headquarters Country
Netherlands
Nasdaq / NYSE Code
PHVS
Market Cap (Mar-08-2026)
1.41
World Region
Europe
World Subregion
Western Europe
Business Sector
Healthcare
Biotechnology
Company Website
PHARVARIS N.V.
Yahoo
Yahoo @ Nasdaq
Company Profile
Pharvaris is a biotechnology sector company related clinical-stage company focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Headquarters is in Netherlands.
IPO Year
2021
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share